Since then, more than ten types of GLP-1 receptor agonists have received FDA approval and been brought to market, and with each new version, their effectiveness has increased
C., Muhammad, A., van der Lely, A
Results vary depending on lifestyle habits and metabolic patterns
Recently, Altimmune reported interim data for its weekly injectable GLP-1/glucagon dual agonist (pemvidutide) in a Phase 2 trial--disappointing levels of discontinuations sent the stock tumbling 55%
Some researchers have reported unexpected pregnancies while on tirzepatide, likely because improved metabolic health can restore ovulation in women with weight-related anovulation
There is no coaching, nutrition program, or fitness layer